H. Lundbeck has signed a deal to purchase NeuronIcon, a Danish biotech firm, for an undisclosed amount. The acquisition will allow the Danish pharmaceuticals group to use NeuronIcon's nerve cell discoveries in developing drugs for serious brain diseases, said Jan Egebjerg, head of Lundbeck's biologic research division.

Full Story:

Related Summaries